José Sereno

177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer

Abstract Brain metastases (BrM) are a frequent and devastating complication of HER2-positive (HER2+) breast cancer (BC), affecting up to 30% of patients with metastatic disease. Although trastuzumab has transformed HER2+ BC treatment, its efficacy against BrM remains limited by b...